

December 6, 2012



**Amarantus**  
BioScience

## Amarantus Bioscience to Present at OneMedForum 2013

SUNNYVALE, Calif., Dec. 6, 2012 /PRNewswire/ -- Amarantus Bioscience, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it will be presenting at the [OneMedForum 2013](#) healthcare conference on Tuesday, January 8<sup>th</sup>, 2013 at 2pm Pacific. *OneMedForum 2013 will be held* at the Sir Francis Drake Hotel during the week of the J.P. Morgan 3<sup>rd</sup> Annual Healthcare Conference in San Francisco. A link to the live webcast of the presentation will be made available to the public prior to the conference.

### About OneMedForum

Established in 2008, [OneMedForum](#) is the conference component of OneMedPlace, which provides an integrated media platform to showcase the best ideas and innovations in health and medicine globally. The media platform also includes: OneMedRadio; OneMedTV, OneMedSentinel; a global database of companies; and OneMedResearch, which tracks promising lesser-known microcap public companies. For more information visit the conference website. [www.onemedforum.com](http://www.onemedforum.com)

### About Amarantus Bioscience, Inc.

Amarantus Bioscience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit [www.Amarantus.com](http://www.Amarantus.com).

### Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug

candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation. This press release does not represent an offer to buy or sell securities.

**Amarantus Bioscience, Inc.**

(408) 737-2734

[pr@amarantus.com](mailto:pr@amarantus.com)

**Investor/Media Contact:**

IR Sense, LLC

Remy Bernarda

415-203-6386

[remy@irsense.com](mailto:remy@irsense.com)

SOURCE Amarantus Bioscience, Inc.